Amuvatinib – 1 mg

Brand:
Cayman
CAS:
850879-09-3
Storage:
-20
UN-No:
Non-Hazardous - /

Amuvatinib is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor α (PDGFRα), and c-Met (IC50s = 10, 40, and 81 nM, respectively).{34322} It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib (Item No. 10483).{34322} Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.{29344,34323,34324}  

 

Out of stock

SKU: 21461 - Category:

Description

A multi-targeted RTK inhibitor that inhibits c-Kit, PDGFRα, and c-Met (IC50s = 10, 40, and 81 nM, respectively); sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination


Formal name: N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide

Synonyms:  HPK56|MP470

Molecular weight: 447.5

CAS: 850879-09-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling